NDAORALTABLET
Approved
Dec 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
RELPAX (eletriptan hydrobromide) by Viatris (2) is 5-ht 1b , 5-ht 1d and 5-ht 1f receptors, has modest affinity for 5-ht 1a , 5-ht 1e , 5-ht 2b and 5-ht 7 receptors. Approved for cluster headache (), migraine, any subsequent attacks. First approved in 2002.
Drug data last refreshed 12h ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RELPAX (eletriptan hydrobromide) is an oral triptan approved in 2002 for acute treatment of migraine and cluster headache. It works by selectively binding to 5-HT1B/1D serotonin receptors on intracranial blood vessels and trigeminal sensory nerves, causing cranial vasoconstriction and inhibiting pro-inflammatory neuropeptide release.
$3MPart D
LOE ApproachingDeclining
Product is in late-stage market maturity with modest Part D utilization (2,442 claims, $3M spend in 2023); expect small, stable brand team focused on maintenance rather than growth.
Mechanism of Action
5-HT 1B , 5-HT 1D and 5-HT 1F receptors, has modest affinity for 5-HT 1A , 5-HT 1E , 5-HT 2B and 5-HT 7 receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide)…
Indications (3)
Worked on RELPAX at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.